Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRENE.L Regulatory News (RENE)

  • There is currently no data for RENE

Director/PDMR Shareholding

12 Aug 2013 07:00

RNS Number : 4192L
ReNeuron Group plc
12 August 2013
 

 

DTR3

 

NOTIFICATION OF TRANSACTIONS OF DIRECTORS/ PERSONS DISCHARGING MANAGERIAL RESPONSIBILITY AND CONNECTED PERSONS

 

All relevant boxes should be completed in block capital letters.

 

1.

Name of the issuer

 

ReNeuron Group plc

2.

State whether the notification relates to (i) a transaction notified in accordance with DR 3.1.2R; or (ii) a disclosure made in accordance with LR 9.8.6R(1); or (iii) in accordance with section 793 of the Companies Act 2006

 

(i)

 

3.

Name of person discharging managerial responsibilities/director

 

Dr. Tim Corn

4.

State whether notification relates to a person connected with a person discharging managerial responsibilities/director named in 3

and identify the connected person

 

Director named in 3.

 

5.

Indicate whether the notification is in respect of a holding of the person referred to in 3 or 4 above or in respect of a non-beneficial interest 1

 

Interest of person named in 3

 

6.

Description of shares (including class), debentures or derivatives or financial instruments relating to shares

 

Ordinary Shares

 

 

7.

Name of registered shareholders(s) and, if more than one, the number of shares held by each of them

 

Person named in 3

 

8.

State the nature of the transaction

 

Placing of Ordinary Shares

9.

Number of shares, debentures or financial instruments relating to shares acquired

 

Acquisition of 200,000 Ordinary Shares

10.

Percentage of issued class acquired (treasury shares of that class should not be taken into account when calculating percentage)

 

0.011%

 

11.

Number of shares, debentures or financial instruments relating to shares disposed

 

 

 

12.

Percentage of issued class disposed (treasury shares of that class should not be taken into account when calculating percentage)

 

 

 

13.

Price per share or value of transaction

 

2.5 pence per Ordinary Share

 

14.

Date and place of transaction

 

9 August 2013

15.

Total holding following notification and total percentage holding following notification (any treasury shares should not be taken into account when calculating percentage)

 

Dr. Tim Corn is interested in a total of 200,000 Ordinary Shares in the Company representing approximately 0.011% of issued Ordinary Shares.

 

16.

Date issuer informed of transaction

 

9 August 2013

 

If a person discharging managerial responsibilities has been granted options by the issuer complete the following boxes

 

17.

Date of grant

 

 

18.

Period during which or date on which it can be exercised

 

19.

Total amount paid (if any) for grant of the option

20.

Description of shares or debentures involved (class and number)

 

21.

Exercise price (if fixed at time of grant) or indication that price is to be fixed at the time of exercise

 

22.

Total number of shares or debentures over which options held following notification

23.

Any additional information

 

 

24.

Name of contact and telephone number for queries

 

Pat Huggins, Reneuron Group Plc

+44 (0)1483 302560

 

 

Name of authorised official of issuer responsible for making notification:

 

Patrick Huggins, Head of Finance and Company Secretary

 

Date of notification: 9 August 2013

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSLLFSETVIAIIV
Date   Source Headline
8th Dec 20227:06 amRNSPositive iPSC data presented at conference
2nd Dec 20224:40 pmRNSSecond Price Monitoring Extn
2nd Dec 20224:35 pmRNSPrice Monitoring Extension
2nd Dec 20222:00 pmRNSPrice Monitoring Extension
2nd Dec 20227:00 amRNSInterim Results
7th Oct 20227:00 amRNSPositive Exosome data presented at US conference
22nd Sep 20227:00 amRNSReNeuron to present new data at Exosome conference
14th Sep 20227:00 amRNSDirectorate and Executive Changes
9th Sep 202210:58 amRNSResult of AGM
2nd Sep 202211:01 amRNSDirector/PDMR Shareholding
1st Sep 20227:00 amRNSBlock Listing Review and Total Voting Rights
15th Aug 20223:25 pmRNSPosting of AR & Accounts & Notice of AGM
1st Aug 20227:00 amRNSDirectorate Change
15th Jul 20227:00 amRNSGrant of Options
14th Jul 20227:00 amRNSShare Purchase by a Director
13th Jul 20227:00 amRNSShare Purchase by a Director
4th Jul 20227:00 amRNSPreliminary Results
1st Jul 20227:00 amRNSFosun Tech Transfer and Supply Agreement update
20th Jun 20227:00 amRNSNotice of Results
3rd May 20227:00 amRNSReNeuron to present at ISCT 2022 in San Francisco
25th Apr 20227:00 amRNSDirector Declaration
23rd Mar 20227:00 amRNSHolding(s) in Company
22nd Mar 20227:01 amRNSDirectorate Changes
22nd Mar 20227:00 amRNSAppointment of Nominated Adviser and Joint Broker
8th Mar 20227:00 amRNSBlock Listing Review and Total Voting Rights
7th Mar 20224:00 pmRNSHolding(s) in Company
2nd Mar 20227:00 amRNSDirector exit arrangements
11th Feb 20224:41 pmRNSSecond Price Monitoring Extn
11th Feb 20224:36 pmRNSPrice Monitoring Extension
11th Feb 20222:38 pmRNSHolding(s) in Company
11th Feb 20227:00 amRNSDirector Change
10th Feb 20229:49 amRNSHolding(s) in Company
9th Feb 202211:59 amRNSHolding(s) in Company
4th Feb 20225:17 pmRNSHolding(s) in Company
28th Jan 20227:00 amRNSInvestor Presentation
26th Jan 20222:06 pmRNSSecond Price Monitoring Extn
26th Jan 20222:01 pmRNSPrice Monitoring Extension
18th Jan 20224:35 pmRNSPrice Monitoring Extension
18th Jan 20222:06 pmRNSSecond Price Monitoring Extn
18th Jan 20222:00 pmRNSPrice Monitoring Extension
18th Jan 202211:05 amRNSSecond Price Monitoring Extn
18th Jan 202211:00 amRNSPrice Monitoring Extension
18th Jan 20229:05 amRNSSecond Price Monitoring Extn
18th Jan 20229:00 amRNSPrice Monitoring Extension
18th Jan 20227:00 amRNSStrategic update
13th Jan 20227:00 amRNSAdditional agreement with Fosun Pharma for CTX
11th Jan 20227:00 amRNSNew Senior Appointment
17th Dec 20212:00 pmRNSDirector Declaration
30th Nov 20217:00 amRNSInterim Results
19th Nov 20217:00 amRNSCTX-iPSC platform data shows commerical potential

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.